To confirm the relevance of TAMs in favoring the aggressiveness of BC cells, we performed double immunofluorescence for CXCR4 and CD163 on tumor tissues of luminal B BC patients from the validation cohort. The gene discussed is CXCR4; the disease is breast cancer.